Cyclodextrin encapsulation of daidzein and genistein by grinding: implication on the glycosaminoglycan accumulation in mucopolysaccharidosis type II and III fibroblasts.

Abstract

This work aimed to investigate the potential effect of cyclodextrin encapsulation on intrinsic ability of daidzein (DAD) and genistein (GEN) to inhibit the glycosaminoglycan (GAG) synthesis in fibroblasts originating from patients with mucopolysaccharidosis (MPS), type II and III. DAD or GEN encapsulation with either 2-hydroxypropyl-β-cyclodextrin or sulphobuthylether-β-cyclodextrin were achieved by neat grinding and were characterised by thermal analysis, X-ray powder diffraction, scanning electron microscopy and solubility testing which confirmed the complexes formation with increased solubility with respect to starting compounds. Both isoflavones, as well as their co-ground cyclodextrin complexes reduced GAG levels in the fibroblasts of MPS II and MPS III patients from 54.8-77.5%, in a dose dependent manner, without any significant cytotoxic effect. Cyclodextrin encapsulation did not change the intrinsically high effect of both DAD and GEN on the GAG level reduction in the treated cells, thus could be considered as a part of combination therapies of MPS.

• Authors: Barbara Fumić, Jasna Jablan, Dominik Cinčić, Marijana Zovko Končić, Mario Jug
• Journal: Journal of microencapsulation (J Microencapsul) Vol. 35 Issue 1 Pg. 1-12 (Jan 2018) ISSN: 1464-5246 [Electronic] England
• PMID: 29168930 (Publication Type: Journal Article)

Chemical References

• Cyclodextrins
• Glycosaminoglycans
• Isoflavones
• daidzein
• Genistein

Topics

• Cells, Cultured
• Cyclodextrins (chemistry, pharmacology)
• Female
• Fibroblasts (metabolism)
• Genistein (chemistry, pharmacology)
• Glycosaminoglycans (metabolism)
• Humans
• Isoflavones (chemistry, pharmacology)
• Male
• Mucopolysaccharidosis I (drug therapy, metabolism)
• Mucopolysaccharidosis II (drug therapy, metabolism)